![Yaakov Naparstek](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Yaakov Naparstek
Corporate Officer/Principal presso The Hebrew University of Jerusalem
Posizioni attive di Yaakov Naparstek
Società | Posizione | Inizio | Fine |
---|---|---|---|
The Hebrew University of Jerusalem | Corporate Officer/Principal | - | - |
Storia della carriera di Yaakov Naparstek
Precedenti posizioni note di Yaakov Naparstek
Società | Posizione | Inizio | Fine |
---|---|---|---|
HBL - HADASIT BIO-HOLDINGS LTD | Direttore/Membro del Consiglio | 26/03/2014 | 23/03/2017 |
Hadassah University Hospital
![]() Hadassah University Hospital Hospital/Nursing ManagementHealth Services Hadassah University Hospital engages in the operation of hospitals and medical centers in Israel and abroad. Its services include hospitalization services, medical services, medical tourism, and research and development. The company was founded in 1934 and is headquartered in Jerusalem, Israel. | Corporate Officer/Principal | - | - |
ProtAb Ltd.
![]() ProtAb Ltd. Pharmaceuticals: MajorHealth Technology ProtAb Ltd. develops drug treatment for rheumatoid arthritis. It develops therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune inflammatory diseases. The company was Founded by Yaakov Naparstek in 2005 and is headquartered in Jerusalem, Israel. | Fondatore | 24/08/2005 | - |
Corporate Officer/Principal | 24/08/2005 | - | |
Verto Medical Ltd.
![]() Verto Medical Ltd. BiotechnologyHealth Technology Verto Medical Ltd. (Verto) is focused on the development of a drug-device product, the Lupusorb column, for the treatment of Lupus disease. It is the first of a series of products for the treatment of severe autoimmune diseases. The Lupusorb column is an extra-corporeal immunoadsorbtion column for use during plasmapheresis treatments and utilizes a highly specific proprietary peptide to selectively remove from circulation antibodies associated with the disease. The company is focused on initiating a first-in-man clinical study and is now completing the last product testing studies required prior to the submission of its clinical trial protocol to regulatory authorities. The upcoming clinical study will be carried out in 10 patients and will determine safety and the ability of the Lupusorb column to reduce the circulating levels of antibodies associated with Lupus disease. | Direttore Tecnico/Scientifico/R&S | 15/10/2009 | - |
Fondatore | 15/10/2009 | - | |
Presidente | - | 15/10/2009 |
Formazione di Yaakov Naparstek
The Hebrew University Hadassah Medical School | Undergraduate Degree |
Statistiche
Distribuzione geografica
Israele | 7 |
Posizioni
Corporate Officer/Principal | 3 |
Founder | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Settori
Health Technology | 3 |
Consumer Services | 3 |
Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
HBL - HADASIT BIO-HOLDINGS LTD | Finance |
Aziende private | 3 |
---|---|
Verto Medical Ltd.
![]() Verto Medical Ltd. BiotechnologyHealth Technology Verto Medical Ltd. (Verto) is focused on the development of a drug-device product, the Lupusorb column, for the treatment of Lupus disease. It is the first of a series of products for the treatment of severe autoimmune diseases. The Lupusorb column is an extra-corporeal immunoadsorbtion column for use during plasmapheresis treatments and utilizes a highly specific proprietary peptide to selectively remove from circulation antibodies associated with the disease. The company is focused on initiating a first-in-man clinical study and is now completing the last product testing studies required prior to the submission of its clinical trial protocol to regulatory authorities. The upcoming clinical study will be carried out in 10 patients and will determine safety and the ability of the Lupusorb column to reduce the circulating levels of antibodies associated with Lupus disease. | Health Technology |
ProtAb Ltd.
![]() ProtAb Ltd. Pharmaceuticals: MajorHealth Technology ProtAb Ltd. develops drug treatment for rheumatoid arthritis. It develops therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune inflammatory diseases. The company was Founded by Yaakov Naparstek in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |
Hadassah University Hospital
![]() Hadassah University Hospital Hospital/Nursing ManagementHealth Services Hadassah University Hospital engages in the operation of hospitals and medical centers in Israel and abroad. Its services include hospitalization services, medical services, medical tourism, and research and development. The company was founded in 1934 and is headquartered in Jerusalem, Israel. | Health Services |
- Borsa valori
- Insiders
- Yaakov Naparstek
- Esperienza